Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus.

Trial Profile

Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms START
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 05 Oct 2012 The primary endpoint data and additional secondary measures will be available in June 2012, and will be reported at the time of the meeting according to the abstract (however, these results were not reported in the abstract).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top